What we’re seeing with ENTA’s recent rise is that many investors have finally decoupled the company from the Mavyret royalty stream and are evaluating ENTA as a bona fide drug-discovery and drug-development outfit.
ENTA used to move up or down strongly based on ABBV’s reported Mavyret sales, but that is no longer the case, evidently.
News 
Market Data 
Discover 
